Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Licence Agreement with the University of California, San Francisco for a Phase 2 Trial of Psilocybin in Methamphetamine Use Disorder Among People with HIV

Rhelion will supply psilocybin for a UCSF-led Phase 2 trial starting November 2026.

What the company is saying

Rhelion Life Sciences, through its subsidiary Filament Health, is highlighting a new licence and supply agreement with the University of California, San Francisco to provide PEX010, its patented botanical psilocybin, for a Phase 2 clinical trial targeting methamphetamine use disorder in people living with HIV. The announcement emphasizes Filament's role as a supplier, not a sponsor, of the trial, and details the rigorous trial design, including quadruple blinding and motivational support therapy. The company underscores the lack of any FDA-approved medication for methamphetamine use disorder, positioning PEX010 as a potential solution in an area of high unmet need. Rhelion also draws attention to Filament's broader reach, supporting over 80 research studies worldwide and holding 78 issued patents across 13 patent families. The involvement of named UCSF investigators and support from the National Institute on Drug Abuse are presented to reinforce institutional credibility. The tone is confident, focusing on operational execution and regulatory compliance rather than speculative outcomes.

What the data suggests

The agreement commits Filament to supply PEX010 in 25 mg and 5 mg capsules, along with regulatory documentation, for a 30-participant, quadruple-blind trial at UCSF's Zuckerberg San Francisco General Hospital. The trial protocol includes random assignment to either 25 mg or 5 mg doses, three preparation and three integration therapy visits per participant, and an optional additional 25 mg session after four weeks. The trial is expected to begin in November 2026 under IND 180587, with Dr. Nicky J. Mehtani as sponsor and Dr. Jennifer Mitchell as co-principal investigator. Filament is not responsible for trial conduct, limiting its exposure to operational risk from the study. The company claims PEX010 supports more than 80 research studies and is available in standardized doses of 1, 5, and 25 mg, with a 0.5 mg dose in development. No financial figures, revenue from this agreement, or commercial uptake data are disclosed. The acquisition of Filament and its IP portfolio was completed April 30, 2026, but no integration or financial impact details are given. The data is specific on operational scope and trial design but does not provide evidence of clinical efficacy or near-term commercial returns.

Analysis

The announcement is factual and measured, focusing on the supply agreement for PEX010 to a UCSF-led Phase 2 trial, with clear disclosure that Filament is not the trial sponsor and is only supplying the drug and regulatory documentation. The tone is positive, highlighting the breadth of Filament's research collaborations and patent portfolio, but does not overstate the immediate commercial or clinical impact. Most claims are realised (agreement signed, acquisition completed, patents held), with forward-looking statements limited to the trial's expected start date and future dosing availability. The benefits from the trial are long-term, as the study has not yet begun and will take time to generate results. The acquisition of Filament and its IP portfolio is a significant capital outlay, but there is no immediate earnings impact disclosed. No profitability or revenue metrics are provided, so the signal cannot be stronger than weak_positive. There is no evidence of narrative inflation or exaggerated claims.

Risk flags

• ●The primary risk is the long timeline to potential value realization, as the Phase 2 trial has not yet begun and will take months or years to generate results, delaying any possible commercial or clinical impact for Rhelion.
• ●There is no guarantee of positive trial outcomes or regulatory progress, as PEX010's efficacy for methamphetamine use disorder remains unproven and the trial's primary endpoints are feasibility, acceptability, safety, and tolerability, not efficacy.
• ●Rhelion is not the sponsor of the trial and has no control over its conduct or outcomes, which limits its ability to influence timelines, data quality, or regulatory submissions.
• ●No financial terms, revenue projections, or commercial milestones are disclosed for this supply agreement, making it impossible to assess the direct economic benefit or return on investment from this arrangement.
• ●The company references a large patent portfolio and broad research support, but provides no detail on monetization, licensing revenue, or competitive positioning, leaving the commercial pathway for PEX010 unclear.

Bottom line

Rhelion's agreement to supply PEX010 for a UCSF-led Phase 2 trial is a credible operational milestone but does not offer near-term financial upside or clinical validation. The company's role is limited to drug supply and regulatory documentation, with no responsibility for trial conduct or outcomes. The trial targets a high unmet need—methamphetamine use disorder in people living with HIV—but is months from initiation and years from producing actionable results. No revenue, cost, or commercial uptake data are disclosed, so the immediate financial impact is indeterminate. The breadth of Filament's research collaborations and patent portfolio is highlighted, but without monetization details, the commercial value remains speculative. Investors should recognize this as a long-dated, high-risk, but potentially high-reward research exposure, with the most important near-term milestone being the actual commencement of the UCSF trial in November 2026.

Announcement summary

(CSE:RHEL) (FSE:4YX0) (OTCQB:TRUFF) Rhelion Life Sciences Corp., through its wholly owned subsidiary Filament Health Corp., develops, manufactures, and supplies PEX010, a patented, standardized, GMP-manufactured botanical psilocybin drug candidate, to clinical research and compassionate access programs at leading institutions worldwide. Filament has entered into a licence and supply agreement with the University of California, San Francisco (UCSF) to supply PEX010 for the Phase 2 trial "PRISM: Psilocybin Recovery Intervention for Stopping Methamphetamine use" (NCT07756736). The trial will enroll 30 participants living with HIV and moderate to severe methamphetamine use disorder, who will be randomly assigned to receive a single monitored dose of PEX010 at either 25 mg or 5 mg, with the 5 mg dose serving as the active comparator. The trial is quadruple blinded, with participants, care providers, investigators, and outcomes assessors all masked to dose. Each dosing session is supported by three preparation and three integration motivational support therapy visits, and eligible participants may receive one additional open label 25 mg session after the four week assessment. The trial is expected to begin in November 2026 at UCSF's site at Zuckerberg San Francisco General Hospital. The primary outcomes are feasibility, acceptability, safety, and tolerability. The trial is conducted under a sponsor-investigator Investigational New Drug application, IND 180587, held by Dr. Nicky J. Mehtani, MD MPH of UCSF, with Dr. Jennifer Mitchell, PhD as co-principal investigator. The work is supported by the National Institute on Drug Abuse. Filament is not the sponsor of the trial and is not responsible for its conduct. Under the agreement, Filament will supply PEX010 in 25 mg and 5 mg capsules for use in the United States, together with regulatory support documentation, including certificates of analysis, batch certificates, the current Investigator's Brochure, and a letter of authorization to reference Filament's drug master files in submissions to the U.S. Food and Drug Administration. There is currently no medication approved by the U.S. Food and Drug Administration for methamphetamine use disorder. Methamphetamine use is associated with poorer outcomes among people living with HIV, including reduced adherence to antiretroviral treatment. PEX010 supports more than 80 academic and philanthropic research studies worldwide and is available in standardized dosing of 1, 5, and 25 mg, with a 0.5 mg dose to follow. On April 30, 2026, Rhelion completed its acquisition of Filament Health Corp., including PEX010 and a portfolio of 78 issued patents across 13 patent families.

Disagree with this article?